Global Health Intrinsic Value
Global Health (MEDANTA) median intrinsic value is ₹627.41 from 9 valuation models (range ₹318–₹1639), vs current price ₹1061.45 — -40.9% downside (Trading Above Calculated Value), margin of safety -69.2%. For current market price and key ratios, visit Global Health share price today.
MEDANTA Valuation Methods Summary — DCF, Graham Number & P/E
Global Health intrinsic value across 9 models vs current price ₹1061.45 — upside/downside and value range per method. Browse MEDANTA financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹318.44 | ₹254.75 - ₹382.13 | -70.0% | EPS: ₹23.56, Sector P/E: 12x |
| Book Value Method | asset | ₹627.41 | ₹564.67 - ₹690.15 | -40.9% | Book Value/Share: ₹627.41, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹672.59 | ₹605.33 - ₹739.85 | -36.6% | Revenue/Share: ₹840.74, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1186.67 | ₹1068.00 - ₹1305.34 | +11.8% | EBITDA: ₹1068.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1569.63 | ₹1255.70 - ₹1883.56 | +47.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹318.44 | ₹286.60 - ₹350.28 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹318.44 | ₹286.60 - ₹350.28 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1638.52 | ₹1474.67 - ₹1802.37 | +54.4% | ROE: 18.7%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹576.71 | ₹519.04 - ₹634.38 | -45.7% | EPS: ₹23.56, BVPS: ₹627.41 |
MEDANTA Intrinsic Value vs Market Price — All Valuation Models
Global Health fair value range ₹318–₹1639 vs current market price ₹1061.45 across 9 valuation models. Compare with MEDANTA fair value to assess whether the stock is under or overvalued.
MEDANTA Intrinsic Value Analysis — Undervalued or Overvalued?
Global Health median intrinsic value ₹627.41, current price ₹1061.45 — Trading Above Calculated Value by 40.9%, margin of safety -69.2%.
What is the intrinsic value of MEDANTA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹627.41 (median value). With the current market price of ₹1061.45, this represents a -40.9% variance from our estimated fair value.
The valuation range spans from ₹318.44 to ₹1638.52, indicating ₹318.44 - ₹1638.52.
Is MEDANTA undervalued or overvalued?
Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading above calculated value by approximately 40.9%.
MEDANTA Financial Health — Key Ratios vs Industry Benchmarks
Global Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.02 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MEDANTA Cash Flow Quality — Operating & Free Cash Flow
Global Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹624 Cr | ₹264 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹612 Cr | ₹392 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹645 Cr | ₹474 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹311 Cr | ₹101 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹242 Cr | ₹123 Cr | Positive Free Cash Flow | 8/10 |